Document is current
Any future updates will be listed below
-
Authors
Camilli, Carlotta https://orcid.org/0000-0002-4858-336X
Hoeh, Alexandra E. https://orcid.org/0000-0002-5123-1760
De Rossi, Giulia https://orcid.org/0000-0001-6163-4590
Moss, Stephen E.
Greenwood, John https://orcid.org/0000-0003-4496-2984
-
Funding
Funding for this research was provided by:
Wellcome Trust (206413/B/17/Z)
UKRI/Medical Research Council UK (G1000466)
The British Heart Foundation (PG/16/50/32182)
Diabetes UK (18/0005856)
- License Information
-
More Information
Article History
Received: 16 October 2021
Accepted: 11 January 2022
First Online: 21 January 2022
Declarations
:
: Not applicable.
: Not applicable.
: JG and SEM are founders and members of the scientific advisory board of a company spun out by UCL Business to commercialize a LRG1 function-blocking therapeutic antibody developed through the UK Medical Research Council DPFS funding scheme. JG and SEM are shareholders of this company and named inventors on three patents related to LRG1 as a therapeutic target.
